Home / Resource Library / Phase III BELINDA: tisa-cel vs standard of care as second line treatment of aggressive B-cell lymphoma

Phase III BELINDA: tisa-cel vs standard of care as second line treatment of aggressive B-cell lymphoma

Results of a study examining CAR T therapy tisagenlecleucel for second line treatment of relapsed large cell lymphomas.